NFKBIA
Reactivité: Humain, Souris, Rat
WB, ELISA
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
ELISA: 1:2000. Western Blot: 1:200 - 1:1000. Immunoprecipitation. Gel Super Shift Assays. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS containing 0.09 % Sodium Azide and 0.5 % Bovine Serum Albumin
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C/-20 °C
Stockage commentaire
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing. Shelf Life: one year from despatch.
Date de péremption
12 months
Antigène
NFKBIA
(Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, alpha (NFKBIA))
Three major forms of IKB like molecules have been identified and each is characterised by multiple copies of ankyrin repeats. IKB alpha and IKB beta appear to be the major regulatory forms of IKB in most cells. These proteins interact with p65 or cRel containing forms of NFkB and block nuclear import by masking the nuclear localisation sequences of NFkB. The activation of NFkB involves the inducible phosphorylation and subsequent degradation of IKB. Immunoblotting easily detects the hyperphosphorylated forms of IKB alpha, but not phosphorylated IKB beta. Interestingly, IKB alpha and IKB beta mediate different NFkB responses. IkB alpha appears to control more transient activation of NFkB in response to an inducer, while IKB beta controls a persistent response. Bcl3 interacts with p50 and p52 containing forms of NFkB, but rather than being an inhibitor it appears to function to stimulate transcription. The degradation of IKB is confirmed by immunoblotting.Synonyms: I kappa B-alpha, I-kappa-B-alpha, IkB-alpha, IkappaBalpha, MAD3, Major histocompatibility complex enhancer-binding protein MAD3, NF-kappa-B inhibitor alpha, NFKBI